Conference call and webcast to be held
at 4:30 p.m. EDT
NEW
HAVEN, Conn., Nov. 3, 2022
/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a
clinical-stage biopharmaceutical company developing an
investigational therapy Haduvio™ (oral nalbuphine ER) for the
treatment of serious chronic cough conditions, today announced that
management will host a conference call and live audio webcast
on Thursday, November 10, 2022, at 4:30 p.m. ET, to
provide a corporate update and review the Company's financial
results for the third quarter ended September 30, 2022.
To participate in the live conference call by phone, please dial
(888) 317 6003 (domestic) or (412) 317 6061 (international) and
provide access code 4950734. A live audio webcast will be
accessible from the 'Investors & News' section on the Company's
website at www.TreviTherapeutics.com. An archived replay of
the webcast will also be available for 30 days on the Company's
website following the event.
About Trevi Therapeutics, Inc.
Trevi
Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and commercialization of the
investigational oral therapy Haduvio™
(nalbuphine ER) for the treatment of serious chronic
cough conditions. The Company has successfully completed a Phase 2
trial of Haduvio for the treatment of chronic cough in
adults with idiopathic pulmonary fibrosis (IPF). Based
on this positive data, Trevi plans to focus future
clinical development on chronic cough conditions, including
IPF, refractory chronic cough, and interstitial lung diseases
(ILDs).
For more information, visit www.TreviTherapeutics.com and follow
the company on Twitter and LinkedIn.
About Haduvio
Haduvio, an investigational
therapy, is an oral extended-release (ER) formulation of
nalbuphine. Nalbuphine is a mixed
ĸ-opioid receptor agonist and µ-opioid
receptor antagonist that has been approved and marketed as an
injectable for pain indications for more than 20 years in the
United States and Europe. The ĸ- and
µ-opioid receptors are centrally and peripherally
active and known to be critical mediators of cough and itch.
Nalbuphine's mechanism of action may also mitigate the risk
of abuse associated with µ-opioid agonists because it
antagonizes, or blocks, µ-opioid receptors.
Parenteral nalbuphine is not currently scheduled as a
controlled substance by the DEA in the United
States or by regulatory authorities in most
of Europe. Trevi intends to
propose Haduvio as the trade name for
nalbuphine ER. Its safety and efficacy have not been
evaluated by any regulatory authority.
Investor Contact
Katie McManus
Trevi Therapeutics,
Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-q3-2022-financial-results-and-provide-a-corporate-update-on-november-10-2022-301668183.html
SOURCE Trevi Therapeutics, Inc.